Here's a fact that should bother every trichology professional: the last drug approved specifically for androgenetic alopecia was finasteride. In 1997. Nearly 30 years ago.
Minoxidil has been around even longer. Since 1988. We've been working with the same two FDA-approved options for decades while the science of hair loss has leapt forward.
That's about to change.
There are three treatments currently in advanced clinical trials that approach hair loss through completely different mechanisms than anything we've had before. None of them are on the market yet, but understanding them now puts you ahead of the curve. Your clients are going to start asking about them, and you need to be the one with the real answer, not the one Googling it in front of them.
Let me break each one down.
Clascoterone is the closest to market, and it's a big deal. It's a topical antiandrogen that blocks androgen receptors directly at the scalp. Think of it as doing what finasteride does, but without going systemic. No hormone changes. No sexual side effects. Applied directly where the problem is.
The Phase 3 trials (SCALP 1 and SCALP 2) enrolled 1,465 patients and showed significant hair count improvements with minimal side effects. If approved, it would be the first new AGA-specific treatment in over three decades.
Why this matters: finasteride works, but a meaningful percentage of men refuse it or discontinue it because of side effect concerns. A topical that blocks androgens locally without systemic absorption solves that problem entirely.
This one is genuinely new science. GT20029 uses something called PROTAC technology, proteolysis-targeting chimera, which sounds complex because it is. But here's what it does in simple terms: instead of just blocking androgen receptors like finasteride or clascoterone, it tags them for destruction. Your body's own cellular cleanup system breaks them down.
The Phase 2 trial data, published in December 2025, showed significant improvements in hair density. And because it's topical and targets the androgen receptors only at the follicle level, the systemic side effect profile is minimal.
Why this matters: blocking a receptor is temporary. Degrading it is a fundamentally different, and potentially more effective, approach. This is entirely new drug science being applied to hair loss for the first time.
PP405 takes a completely different angle. Instead of targeting androgens, it targets the mitochondrial pyruvate carrier (MPC) in hair follicle stem cells. In miniaturized follicles, those stem cells go dormant. PP405's mechanism is designed to wake them back up.
The Phase 1 trial confirmed that 7 days of topical application was safe and well-tolerated, and, here's the key part, showed statistically significant activation of hair follicle stem cells. That's proof of mechanism in humans. Not just in a petri dish. Not in mice. In people.
Why this matters: this is the first drug specifically designed to reactivate dormant follicle stem cells. If the later-stage trials confirm efficacy, it could address a category of hair loss that current treatments can't, follicles that have been dormant for years.
How They Compare
| Treatment | Mechanism | Application | Trial Stage |
|---|---|---|---|
| Clascoterone | Blocks androgen receptors at the scalp | Topical | Phase 3 ✓ |
| GT20029 | Degrades androgen receptors via PROTAC | Topical | Phase 2 ✓ |
| PP405 | Reactivates dormant follicle stem cells | Topical | Phase 1 ✓ |
| Finasteride (1997) | Inhibits 5-alpha reductase systemically | Oral | FDA Approved |
| Minoxidil (1988) | Vasodilator, increases blood flow to follicle | Topical | FDA Approved |
What This Means for You as a Practitioner
None of these are available to prescribe or recommend yet. But that's not the point. The point is what they tell us about where the science is heading, and how you should be positioning yourself.
Hair loss treatment is moving away from one-size-fits-all systemic drugs and toward targeted, topical, mechanism-specific therapies. The professionals who understand the underlying mechanisms, androgen signaling, stem cell biology, follicle miniaturization pathways, will be the ones who can guide their clients through the next generation of treatments with confidence.
Your clients are already seeing headlines about these. "New hair loss cure!" "Revolutionary treatment!" The internet is full of hype with zero context. You need to be the person who can actually explain what's happening, what's real, what's still in trials, and what it means for their specific situation.
That's the difference between a professional and someone who just does treatments. A professional understands the science underneath.
What to Watch For
Clascoterone is the closest, keep an eye on FDA approval announcements. If approved, it will likely be available by prescription and could become a first-line topical for AGA patients who can't or won't take finasteride.
GT20029 is entering Phase 3 trials. If the results hold, PROTAC-based hair loss treatment could be available within 3-5 years. This is the one that excites researchers the most because the mechanism is so different from everything else.
PP405 is earlier stage, but the stem cell reactivation angle is the most intriguing long-term play. If it can reliably reactivate dormant follicles, it addresses a gap that no current treatment fills.
The Bottom Line
We're entering the most active period of hair loss drug development in decades. Three new treatments with three entirely different mechanisms are moving through clinical trials right now. The landscape is going to look very different in 3-5 years, and the professionals who understand the science today will be the ones leading the conversation tomorrow. Stay informed. Stay current. This is what separates a trichology professional from everyone else.
Sources
Phase 3 SCALP Study on Clascoterone for Androgenetic Alopecia, HCPLive
GT20029 Phase 2 Trial Results, Bauman Medical
New Topical Agent PP405 for Alopecia, Dermatology Times
Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment (2025). PubMed Central
Updates in Treatment for Androgenetic Alopecia (2025). PubMed Central